TrialsgrambetaRCTs are beautiful

MAIA

2019

Daratumumab + Lenalidomide/Dex in Transplant-Ineligible Myeloma

In 737 patients with newly diagnosed transplant-ineligible multiple myeloma, daratumumab + lenalidomide + dexamethasone improved progression-free and overall survival compared with lenalidomide + dexamethasone.

Result

Efficacy: Progression-free survivalHR 0.56

Below 1 favours daratumumab + lenalidomide + dexamethasone, above 1 favours lenalidomide + dexamethasone.

Also reported: MRD-negative 24.2% vs 7.3%. 5-yr OS 66.3% vs 53.1% (HR 0.68).

Original publication
Subtopic
Transplant-ineligible NDMM
Design
Open-label RCT
Relevance
Important: one of several pillars.
Source
Facon T, et al. N Engl J Med. 2019;380(22):2104-2115; Facon T, et al. Lancet Oncol. 2021;22(11):1582-1596.doi 10.1056/NEJMoa1817249

Discussion & critique

Established anti-CD38 in front-line myeloma for patients ineligible for transplant. The principle has since been extended to transplant-eligible disease.